

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC10 Rec'd PCT/PTO 15 JUL 2005

PCT

In re Patent Application of

NARIMATSU et al

Atty. Ref.: 159-86

Serial No. 10/524,505

Group: Unassigned

Filed: February 14, 2005

Examiner: Unassigned

For: NOVEL N-ACETYLGALACTOSAMINE TRANSFERASES
AND NUCLEIC ACIDS ENCODING THE SAME

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 15, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

159-86

10/524,505

APPLICANT

NARIMATSU et al

FILING DATE

GROUP

February 14, 2005

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Kawar et al, The Journal of Biological Chemistry, 2002, Vol. 277, No. 38, pp 34924-34932
	Sato et al, The Journal of Biological Chemistry, 2003, Vol. 278, No. 48, pp 47534-47544
	Gotoh et al, FEBS Letters, 2004, Vol. 562, pp 134-140
	Sugita et al, The Journal of Biological Chemistry, 1989, Vol. 264, No. 25, pp 15028-15033
	Helling et al, Eur. J. Biochem. 1991, Vol. 200, pp 409-421
	Weisshaar et al, Eur. J. Biochem. 1991, Vol. 195, pp 257-268
	White et al, The Journal of Biological Chemistry, 1995, Vol. 270, No. 41, pp 24156-24165
	Bennett et al, The Journal of Biological Chemistry, 1996, Vol. 271, No. 29, pp 17006-17012
	Bennett et al, The Journal of Biological Chemistry, 1998, Vol. 273, No. 46, pp 30472-30481
	Bennett et al, The Journal of Biological Chemistry, 1999, Vol. 274, No. 36, pp 25362-25370
	Bennett et al, FEBS Letters, 1999, Vol. 460, pp 226-230
	White et al, Gene, 2000, Vol. 246, pp 347-356
	Toba et al, Biochimica et Biophysica Acta, 2000, Vol. 1493, pp 264-268
	Nagata et al, The Journal of Biological Chemistry, 1992, Vol. 267, No. 17, pp 12082-12089
	Yamamoto et al, The Journal of Biological Chemistry, 1990, Vol. 265, No. 2, pp 1146-1151
	Xu et al, The Journal of Biological Chemistry, 1999, Vol. 274, No. 41, pp 29390-29398
	Guo et al, FEBS Letters, 2002, Vol. 524, pp 211-218
	Ishizuka et al, J. Carbohydrate Chemistry, 1999, Vol. 18, No. 5, pp 523-533

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)